# Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Source: https://onco.cc/trials/nct05027776/  
OnCo record `nct05027776` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of 2-doses Group among 9-14 years in cervical cancer and vaginal cancer, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.

## Summary

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years is a phase 3 interventional study registered as NCT05027776 by Shanghai Bovax Biotechnology Co., Ltd., with 1348 participants planned, started 2021-09-15 and due to reach its primary completion in 2023-11-22. Interventions recorded: 2-doses Group among 9-14 years, 3-doses Group among 9-19 years and 3-doses Group among 20-26 years.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05027776
- Phase: 3
- Setting: Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial
- Sponsor: Shanghai Bovax Biotechnology Co., Ltd.
- Enrolled: 1348

## Sources

- ClinicalTrials.gov NCT05027776: https://clinicaltrials.gov/study/NCT05027776

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Vaginal cancer](https://onco.cc/cancers/vaginal/)

---
JSON: https://onco.cc/api/v1/entities/nct05027776.json